Core Insights - The meeting between U.S. President Trump and Novartis CEO Vas Narasimhan highlighted the company's plans to build 11 factories in the U.S. due to tariff policies [1][2] - Novartis is progressing with the construction of manufacturing and research facilities in North Carolina and California, and plans to establish a new factory in Florida to expand its radioligand therapy manufacturing network [2] Company Developments - Novartis announced plans to invest $23 billion in the U.S. to build and expand 10 facilities following threats of drug import tariffs from the Trump administration [2]

智通财经APP获悉，近日，晶泰科技(02228)孵化企业默达生物(META Pharmaceuticals Inc.)宣布，其针对 炎症性肠病(IBD)开发的首个临床开发候选分子(PCC)MP-5342已确定，目前正积极准备新药临床试验 (IND)申请，预计最早于2026年下半年启动正式临床试验注册。MP-5342是晶泰科技赋能默达生物开发 的全球首款口服小分子乳酸脱氢酶(LDH)抑制剂。 随着晶泰科技参与发现和优化的创新药管线陆续进入临床阶段，公司将持续积累研发数据驱动AI算法 迭代升级，赋能更多合作伙伴加速源头创新突破，推动全球突破性疗法更快惠及患者，加速兑现人工智 能在生物医药领域的巨大社会价值与经济潜力。 关于默达生物 默达生物(META Pharmaceuticals Inc.)是一家专注于自身免疫疾病及代谢疾病药物研发的创新药物公司， 由AI制药先锋企业晶泰科技、Forcefield Ventures、IMO Ventures共同孵化，天图资本、雅亿资本、方圆 资本、新产业创投、德迅投资、博普资本参与投资。默达生物基于前沿的新兴生物学理论，通过调节细 胞新陈代谢的活力实现对免疫系统功能及其他生理系 ...

Core Viewpoint - The Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, accusing the company of bribing healthcare providers to prioritize its drugs over alternatives [1][2]. Group 1: Allegations and Legal Context - Sanofi is accused of establishing programs that provide services to healthcare providers, which allegedly constitutes bribery under the Texas Medicaid Fraud Prevention Act [1]. - The Texas Attorney General's office is seeking over $1 million in monetary relief, including civil penalties and an injunction to stop any further illegal activities [2]. Group 2: Company Response - Sanofi stated that the services were set up to comply with relevant federal and state laws and aimed to assist patients rather than influence doctors' prescribing decisions [2]. - The company emphasized that the government's intervention is unrelated to the merits of the case and that it is fully defending itself against the lawsuit [2].

（原标题：刚刚，暴跌！直线跳水！） 【导读】日本股市震荡下挫，韩国股市再创新高 中国基金报记者 李智 2月20日，日韩股市开盘涨跌不一，日本股市震荡下挫，日经225指数跌幅扩大至1.3%，最新报56761.57 点。 2月20日，日本总务省发布的数据显示，日本1月核心CPI同比上升2%，为2024年1月以来最小升幅，预 期升2%，前值升2.4%；整体CPI同比上升1.5%，自2022年3月以来首次降至2%以下，预期升1.6%，前值 升2.1%。 个股方面，日本制药股走低，住友制药直线下挫，一度大跌超10%。 当地时间2月5日，特朗普正式推出了TrumpRx.gov网站，此前16家全球最大制药商已与特朗普达成协 议，为美国人提供"最惠国"价格的药品，以换取美国关税豁免。 此外，野村控股、全日本航空、东京电子、软银集团等跌幅居前。 消息面上，软银旗下SB Energy公司将在俄亥俄州开发一个价值330亿美元的天然气项目，这是日本在承 诺向美国投资5500亿美元框架下的首批投资之一，同时还包括得克萨斯州的一个原油出口码头和佐治亚 州的一个合成金刚石处理工厂。 朋友们好，今天是大年初四，一起来看下日韩市场情况及资讯。 ...

智通财经APP获悉，石四药集团(02005)跌超7%，截至发稿，跌7.28%，报2.8港元，成交额257.58万港 元。 消息面上，石四药集团发布公告，预计2025年度溢利将较上年度的10.61亿港元下降45%-60%。主要由 于2024年一季度国内流感爆发以致静脉输液及其他药品市场需求量旺盛，但截至2025年12月31日止的整 个年度因国内没有大规模流行病发生叠加医保控费导致药品终端销量下降；各种形式的带量采购(包括 国家药品集采及地方联盟集采)范围扩大以及国内外行业竞争加剧带来持续的价格压力；及盐酸溴己新 安瓿注射液因不再通过国家药品集采销售而营业额有所减少。 ...

【导读】日本股市震荡下挫，韩国股市再创新高 中国基金报记者 李智 朋友们好，今天是大年初四，一起来看下日韩市场情况及资讯。 日本股市震荡下挫 住友制药一度大跌超10% 2月20日，日韩股市开盘涨跌不一，日本股市震荡下挫，日经225指数跌幅扩大至1.3%，最新报56761.57 点。 | < w | | 日经225(N225) | | | Q | | --- | --- | --- | --- | --- | --- | | | | 02-20 09:24:01 | | | | | 56761.57 | 昨收 | 57467.83 | 成交额 | | 0 | | -706.26 | -1.23% 今开 | 56979.74 | 成交量 | | 0 | | 上 涨 | 49 中 盘 | 0 | 下 跌 | | 176 | | 最高价 | 56979.74 市盈率 | 22.2 | 近20日 | | 5.72% | | 最低价 | 市净率 56732.05 | 2.55 | 今年来 | | 12.76% | | 盯盘 因春节假期,A股于2月16日至2月23日休市 | | | | | × | | 分时 | 五日 日K ...

【导读】日本股市震荡下挫，韩国股市再创新高 朋友们好，今天是大年初四，一起来看下日韩市场情况及资讯。 日本股市震荡下挫 住友制药一度大跌超10% 当地时间2月5日，特朗普正式推出了TrumpRx.gov网站，此前16家全球最大制药商已与特朗普达成协议，为美国人提供"最惠国"价格的药品，以换取美国 关税豁免。 此外，野村控股、全日本航空、东京电子、软银集团等跌幅居前。 | 名称 | 现价 | 涨跌幅 = | 总市 -- | | --- | --- | --- | --- | | 住友制药 | 2718.0 | -7.33% | 10815亿 | | 4506.T | | | | | 野村控股 | 1402.5 | -3.87% | 44369 Z | | 8604.T | | | | | 全日本航空 | 3268.0 | -3.71% | 15827亿 | | 9202.T | | | | | 东海客运 | 4637.0 | -3.50% | 47761亿 | | 9022.T | | | | | 铃木汽车 | 2305.0 | -3.46% | 45284亿 | | 7269.T | | | | | 雅马哈发 ...

Market Overview - The Hong Kong stock market opened lower on the first trading day after the holiday, with the Hang Seng Index down 0.18% at 26,657.84 points, the Hang Seng Tech Index down 0.69% at 5,330.61 points, and the National Enterprises Index down 0.19% at 9,052.67 points. The Red Chip Index, however, rose by 0.79% to 4,415.05 points [1] Company Performance Forecasts - Several companies in Hong Kong are facing significant profit declines for 2025. - Stone Four Pharmaceutical Group (02005.HK) expects a net profit of approximately HKD 1.061 billion, a decrease of 45% to 60% year-on-year [2] - Shougang Resources (00639.HK) anticipates a net profit between HKD 600 million to HKD 700 million, reflecting a year-on-year decline of about 53% to 60% [3] - Pearl River Shipping (00560.HK) projects a net profit between HKD 41 million to HKD 55 million, down 53% to 65% year-on-year [4] - Goodbaby International (01086.HK) expects a net profit decline of 35% to 45%, primarily due to reduced gross margins and increased income tax [5] - Hanyuan Holdings (00439.HK) has issued a profit warning, forecasting a net loss of approximately HKD 130 million to HKD 150 million for 2025 [6] - In contrast, China New Town (01278.HK) has issued a profit alert, expecting a net profit of approximately RMB 76 million for 2025 [7] Biopharmaceutical Sector Developments - The biopharmaceutical sector is experiencing positive developments with several new drug approvals. - Fuhong Hanlin (02696.HK) announced that its HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection) for treating multiple myeloma has received FDA approval for a Phase 1 clinical trial [8] - CSPC Pharmaceutical Group (01093.HK) has also received FDA approval to conduct clinical trials for its GLP-1/GIP receptor dual agonist long-acting injection [8] - Bokan Vision Cloud-B (02592.HK) reported that its CBT-199 new drug clinical trial application has been approved for safety advancement [8] - Changfeng Pharmaceutical (02652.HK) has been included in the Hang Seng Composite Index, effective in the next index review cycle [9] Stock Buybacks - Xiaomi Group-W (01810.HK) repurchased 1.5 million shares for approximately HKD 54.7041 million, with a buyback price between HKD 36.38 and HKD 36.50 [10] - NetEase Cloud Music (09899.HK) repurchased 92,400 shares for approximately HKD 14.9949 million, with a buyback price between HKD 160.3 and HKD 163.7 [10] - Other companies such as Geely Automobile (00175.HK), Meitu (01357.HK), and Tanwan Games (09890.HK) also engaged in stock buybacks [10] Institutional Insights - Huatai Securities suggests that the current market volatility is high, with key variables influenced by U.S. stock performance, holiday consumption data, and AI technology advancements. They recommend a balanced allocation, focusing on sectors benefiting from AI progress, such as semiconductors, specialty consumption, and electrical equipment [12] - Daiwa Capital Markets notes that the mainland internet healthcare sector is entering a new phase, driven by AI innovation and policy support, despite ongoing profitability challenges [13] - Analysts from ING indicate that the recent decline in gold prices is a corrective pause rather than the start of a deep pullback, with expectations of stronger demand as market liquidity in Asia recovers [13]

Major Events - Ying Si Intelligent (03696), Tu Datong (02665), and Changfeng Pharmaceutical (02652) have been included in the Hang Seng Composite Index [1] - Hansoh Pharmaceutical (03692) has received EU approval for the marketing of Amivantamab for monotherapy [1] - Bole Vision Cloud-B (02592) has had its clinical trial application for CBT-199 approved, recognized as safe to proceed [1] - CSPC Pharmaceutical Group (01093) has received clinical trial approval in the US for a GLP-1/GIP receptor dual agonist long-acting injection [1] - CSPC Pharmaceutical Group (01093) has also received clinical trial approval in China for Ropivacaine long-acting injection (SYH9089) [1] - Fuhong Hanlin (02696) has received FDA approval for the Phase I clinical trial application of HLX15-SC for the treatment of multiple myeloma [1] Financial Data - Shougang Resources (00639) issued a profit warning, expecting a net profit attributable to shareholders of approximately HKD 600 million to 700 million for the fiscal year 2025 [1] - Shijiazhuang Pharmaceutical Group (02005) issued a profit warning, anticipating a year-on-year decline in net profit attributable to shareholders of approximately 45% to 60% [1] - Goodbaby International (01086) issued a profit warning, expecting a year-on-year decline in net profit of approximately 35% to 45% for 2025 [1] - Suoteng Juchuang (02498) reported continued growth in sales of laser radar products for fiscal year 2025, achieving profitability for the first time in Q4 [1]

智通财经APP讯，翰森制药(03692)公布，于2026年2月12日，集团创新药甲磺酸阿美替尼片(中国商品 名：阿美乐®，海外商品名：Aumseqa®)单药治疗已于欧盟获批上市，用于：(i)具有表皮生长因子受体 (EGFR)外显子19缺失或外显子21(L858R) 置换突变的晚期非小细胞肺癌(NSCLC)成人患者的一线治疗， 以及(ii)晚期 EGFR T790M突变阳性NSCLC成人患者的治疗。此次批准由欧盟委员会(EC)基于欧洲药品 管理局(EMA)人用药品委员会(CHMP)的积极意见作出。 ...